Connect with us

health

Nigeria expands free health tests for people living with HIV/AIDS

Published

on

Nigeria begins providing free annual liver and kidney function tests for people living with HIV/AIDS through expanded health insurance coverage.

adron lemon friday

The Federal Government has begun providing people living with HIV/AIDS (PLHIV) access to free annual liver and kidney function tests under expanded health insurance coverage.

Also read: Untreated Vaginal Infection Can Lead to Infertility, Experts Warn

Minister of State for Health and Social Welfare, Dr. Iziaq Salako, announced the initiative during the 2025 World AIDS Day commemoration in Abuja, organised by the National Agency for the Control of AIDS (NACA) and partners.

The event carried the theme: “Overcoming disruption: Sustaining Nigeria’s HIV response.”

World AIDS Day, observed annually on December 1, raises awareness about HIV/AIDS, promotes global solidarity, and reviews progress in combating the epidemic.

Salako said the government is moving towards full integration of HIV, tuberculosis, malaria, nutrition, and the National AIDS, Viral Hepatitis and STIs Control Programme into a single, accessible service.

“This integrated approach will ensure that children and adolescents can access multiple essential services during a single visit, thereby improving health outcomes,” he explained.

He also highlighted a recent decision by the National Council on Health to lower the consent age for voluntary HIV counselling and testing from 18 to 14 years, boosting testing among adolescents and promoting early diagnosis and care.

The Minister further encouraged states to integrate the National Clinical Mentorship Programme into their annual operational plans to ensure patients remain on treatment and prevent loss to follow-up.

“I call on all stakeholders—states, partners, civil society, communities, and the private sector—to strengthen collaboration, scale innovation, and accelerate our march toward the 2030 goal of ending AIDS as a public health threat,” he said.

Dr. Temitope Ilori, NACA Director-General, reported that Nigeria is on track to meet the 2030 target of ending HIV, achieving an 87–98–95 performance towards global 95–95–95 targets.

“Eighty-seven per cent of people living with HIV in Nigeria know their status; 98 per cent of those are on life-saving treatment, and 95 per cent of those on treatment have achieved viral suppression,” she said.

Abdulkadiri Ibrahim, President of the Network of People Living with HIV and AIDS in Nigeria, stressed the need for domestic funding, improved community engagement, and greater access to viral load testing.

UN Resident Representative Elsie Attafuah highlighted the importance of domestic financing, human rights protection, community empowerment, and health system strengthening to sustain Nigeria’s HIV response.

Also read: Ogun East Residents Regain Sight through Gbenga Daniel Eye Care Outreach

“Together, we will sustain the response. Together, we will overcome distractions. Together, we will build a future where every person can live with health, dignity, and hope,” she said.

68 / 100 SEO Score

health

FCCPC Moves Against Producers Over Poorly Fortified Oil, Salt

Published

on

FCCPC orders producers to comply with food fortification standards after a survey found inadequately fortified vegetable oil and salt in Nigerian markets

(more…)

adron lemon friday

68 / 100 SEO Score
Continue Reading

health

UK Tests Five-Day Breast Cancer Radiotherapy in Major Trial

Published

on

The UK is testing five-day breast cancer radiotherapy in a major trial that could reduce hospital visits and treatment costs for patients

The United Kingdom has launched a major clinical trial involving more than 1,000 participants to determine whether breast cancer radiotherapy can be shortened from three weeks to five days without compromising its effectiveness in preventing the disease from returning.

Also read: Grey CEO Urges Africa to Ditch Dollar for Trade

adron lemon friday

The government-funded FAST-Forward Boost trial, being conducted at 39 hospitals across the UK, will investigate whether a shorter course of radiotherapy combined with an additional targeted dose, known as a boost, can provide effective treatment for patients following breast cancer surgery.

The UK Department of Health and Social Care announced the development on Friday, October 30, describing the study as part of efforts to improve cancer treatment and make care more convenient for patients.

Led by the Institute of Cancer Research in London and funded by the National Institute for Health and Care Research, the study aims to recruit 4,830 participants by 2028.

Those enrolled will be followed up for five years, with results expected in 2033.

If the approach proves successful, it could reduce the number of hospital visits required by patients, potentially saving them 10 journeys compared with the existing three-week treatment schedule.

The department said the shorter schedule could also reduce transport expenses and the time patients spend away from work and family.

It could additionally ease pressure on the National Health Service by freeing up radiotherapy capacity for other patients.

Health and Social Care Secretary Yvette Cooper said the trial reflected the country’s efforts to use medical research to improve cancer care.

“This trial shows how the UK is using our world beating research capabilities to pursue huge improvements and transformations in cancer treatment for patients,” she said.

Why the radiotherapy trial matters

Radiotherapy uses carefully targeted radiation to destroy cancer cells or prevent them from growing.

For many people with breast cancer, it is recommended after surgery to reduce the risk of the disease returning in the treated area.

A treatment boost involves delivering an additional dose of radiation to the area considered to have a higher risk of recurrence, usually the site where the tumour was removed.

The FAST-Forward Boost trial is examining how this additional treatment can be incorporated into a shorter schedule.

Reducing treatment from three weeks to five days could make a considerable difference to patients who must travel regularly to hospitals.

The impact may be particularly significant for people living far from specialist cancer centres, those with limited transport options and patients balancing treatment with employment or family responsibilities.

However, the trial is designed to establish whether the shorter approach is effective and safe for the patients being studied. Its results will be important in determining whether the treatment schedule can become a wider option in clinical practice.

UK expands breast cancer screening efforts

The announcement comes as the British government intensifies efforts to improve breast cancer screening, encourage early diagnosis and strengthen support for patients.

The Department of Health and Social Care said screening uptake among women receiving their first invitation had risen to 63.6 per cent, its highest level in a decade.

Despite the improvement, around four in 10 women invited for their first screening appointment still do not attend.

The government is also working with the National Institute for Health and Care Research and NHS England on studies examining how artificial intelligence could support the analysis of mammograms.

The technology is being explored as a way to assist the assessment of breast screening images, although its role and effectiveness must be established through appropriate research and clinical evaluation.

In addition, the government has partnered with breast cancer charity Breast Cancer Now for three years to help women recognise symptoms, find reliable information and access support after treatment.

Together, the initiatives reflect a broader approach to breast cancer care, combining screening, research into treatment improvements and support for people living with the disease.

Also read: Grey CEO Urges Africa to Ditch Dollar for Trade

For now, the five-day radiotherapy approach remains under investigation. With final results not expected until 2033, the FAST-Forward Boost trial will need to establish whether reducing treatment time can deliver comparable cancer control while maintaining patient safety.

65 / 100 SEO Score
Continue Reading

health

DR Congo Faces Deadly Ebola Surge, WHO Warns

Published

on

The DR Congo Ebola outbreak is recording 50 to 80 new confirmed cases daily, with about 10,000 cases and nearly 5,000 deaths reported

(more…)

adron lemon friday

57 / 100 SEO Score
Continue Reading

Trending News